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INTRODUCTION:
COVID-19 has been frequently cited as a condition causing a pro-inflammatory state
leading to hypercoagulopathy and increased risk for venous thromboembolism. This
condition has thus prompted prior studies and screening models that utilize D-dimer for
pulmonary embolism (PE) into question. The limited research to date has failed to
provide tools or guidance regarding what COVID-19 positive patients should receive
pulmonary CT angiography screening. This knowledge gap has led to missed diagnoses,
CT overutilization, and increased morbidity and mortality.

OBJECTIVE:
The purpose of this study was to examine the utility of the quantitative D-dimer lab
marker in a convenience sample of 426 COVID-19 positive patients to assist providers in
determining the utility of pulmonary CT angiography.

METHODS:
The authors conducted a retrospective analysis on all COVID-19 positive patients within
the Henry Ford Medical System between March 1st, 2020 through April 30th, 2020 who
received pulmonary CT angiography and had a quantitative D-dimer lab drawn within 24
hours of CT imaging.

RESULTS:
Our sampling criteria yielded a total of n = 426 patients, of whom 347 (81.5%) were
negative for PE and 79 (18.5%) were positive for PE. The average D-dimer in the negative
PE group was 2.95 μg./mL. (SD 4.26), significantly different than the 9.15 μg./mL. (SD
6.80) positive PE group (P < 0.05; 95% CI -7.8, -4.6). Theoretically, applying the
traditional ≤ 0.5 μg./mL. D-dimer cut-off to our data would yield a sensitivity of 100% and
specificity of 7.49% for exclusion of PE. Based on these results, the authors would be able
to increase the D-dimer threshold to < 0.89 μg./mL. to maintain their sensitivity to 100%
and raise the specificity to 27.95%. Observing a D-dimer cut-off value of ≤ 1.28 μg./mL.
would reduce sensitivity to 97.47% but increase the specificity to 57.93%.

CONCLUSIONS:
These study results support the utilization of alternative D-dimer thresholds to exclude
PE in COVID-19 patients. Based on these findings, providers may be able to observe
increased D-dimer cut-off values to reduce unnecessary pulmonary CT angiography
scans.

INTRODUCTION
In late 2019, a new strain of coronavirus known as severe

a
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acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or
“COVID-19” was discovered.1 The majority of the first
COVID-19 cases were either asymptomatic or resulted in
relatively mild disease with a broad range of symptoms.
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During later 2020, thrombotic complications emerged as
important sequelae contributing to significant morbidity
and mortality in COVID-19 patients.2 More patients infected with COVID-19 may now be predisposed to thrombotic disease such as pulmonary embolism (PE) due to excessive inflammation, platelet activation, endothelial
dysfunction, and stasis.3
In one 2020 US report of over 370,000 symptomatic confirmed COVID-19 patients, shortness of breath was cited to
be present in 29% of cases.4 Similar to COVID-19, PE can
have a wide range of presenting symptoms but the most
common being shortness of breath.5 This overlap of symptoms and predisposition for thrombotic complications has
posed a challenge for clinicians to promptly identify PE in
COVID-19 patients. Rapid confirmation or exclusion of PE
is vitally important for initiating appropriate therapy with
anticoagulation.
Traditionally, the D-dimer lab marker (normally ≤ 0.5
μg./mL.) has been utilized in conjunction with clinical probability assessments to rule out PE.6 When elevated, the Ddimer should prompt further diagnostic imaging to identify
PE, specifically, pulmonary CT angiography. Despite the increased risk of PE in COVID-19 patients, there remains no
validation or consensus on D-dimer values and when to obtain pulmonary CT angiography.
PURPOSE OF STUDY

The purpose of this retrospective study was to examine the
utility of quantitative D-dimer lab values in a convenience
sample of confirmed COVID-19 patients to assist providers
considering the need for pulmonary CT angiography to confirm or exclude PE.

METHODS
After IRB project approval was obtained, the authors first
conducted a retrospective analysis of all confirmed
COVID-19 patients who received pulmonary CT angiography. Patients were further classified as being positive or
negative for PE. Following this initial electronic health
record (EHR) data extraction, the authors’ primary endpoint
was to evaluate the quantitative D-dimer value between
these two sample subgroups. Additional demographic and
clinical patient information (e g., age, gender, presence of
infiltrate on chest X-ray or CT, and mortality) were collected. Infiltrate was defined as an abnormal substance
within the interstitium or alveoli of the lungs.
Study data were collected using the EPIC Workbench EHR
from the Henry Ford Health System. An initial data report
was generated by the Principal Investigator (GM) on May
15th, 2020 from all patients who tested positive for
COVID-19 and received a pulmonary CT angiography during
their ED visit or inpatient hospitalization. The authors included data points spanning from March 1st through April
30th, 2020. This initially yielded 605 unique cases that were
reduced to 426 patients after applying our inclusion and exclusion criteria.
Chart reviews by authors GM and AE of each eligible patient were utilized to ensure each patient was positive for
COVID-19, had received pulmonary CT angiography, and

had a documented D-dimer lab value obtained within 24
hours of the CT being performed. If a sample patient had
received multiple (i.e., routinely ordered) D-dimer values,
the D-dimer values that were drawn closest to the time the
CT were completed was in analyses. In contrast, individuals who did not have a quantitative D-dimer within 24 hours
were excluded. This approach was utilized by the authors to
account for daily D-dimer values typically found in patients.
Furthermore, charts which were marked privacy restricted by EPIC (e g., prisoners and healthcare system employees) were excluded to maintain confidentiality. Finally,
patients who underwent pulmonary CT angiography which
were determined to be inadequate (i.e., unable to exclude
PE) by the radiologist were excluded. Inadequate CT’s were
most commonly attributed to poor image quality due to motion artifact (i.e., patient movement) and/or contrast bolus timing leading to poor contrast enhancement. However,
CTs that were read as having a “limited evaluation” and still
able to exclude pulmonary embolism to any degree were included.
DATA ANALYSES

All analyses were performed by author RJ using Minitab Statistical Software (State College, PA) or Vassarstats.net online calculator.7,8 Categorical data were summarized as
counts and percentages, and continuous data were summarized as means with corresponding standard deviations.
Between-group mean differences were compared by calculating t-tests for independent measures. Categorical data
were compared using the chi-square test for association.
Throughout this study, a p-value ≤ 0.05 (two-tailed) was
considered statistically significant.
Sensitivities and specificities of D-dimer lab values for
PE exclusion were calculated using different thresholds.
Thresholds were chosen based on the distribution of our
sample population data, with the overall goal of attempting
to attain a PE sensitivity of 100%.

RESULTS
SAMPLE CHARACTERISTICS

Our sample population was gathered from the Henry Ford
Health System between March 1st through April 30th, 2020.
After initial data extractions, a total sample of n = 426
(70.4%) patients were included in our analytic sample from
an initial total of 605. The gender distribution of our sample
included 209 males (49.1%) and 217 females (50.9%). The
mean age in years for our sample population was 61.62
(SD 16.56) with a range of 19 to 99, further depicted in
histogram form with superimposed normal distributional
curve. (Figure 1).
MAIN RESULTS

Of the total 426 sample patients, 347 (81.5%) were negative
for PE and 79 (18.5%) were positive for PE. The average Ddimer in the “negative for PE” group was 2.95 μg./mL. (SD
4.26) and significantly different compared to 9.15 μg/mL
(SD 6.80) in the “positive for PE” group (P < 0.05) (Table 1).
Applying the traditional ≤ 0.5 μg./mL. D-dimer threshold
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Table 1. Main results comparing negative and positive pulmonary embolism subgroups.
Group

N (%)

Average D-dimer (SD) (μg./mL.)

Negative for PE

347 (81.5)

2.95 (4.26)

Positive for PE

79 (18.5)

9.15 (6.80)

PE = Pulmonary Embolism

Table 2. Sensitivity and specificity for pulmonary embolism at specific D-dimer thresholds
within our sample population. Includes counts of PE present or absent.
D-dimer Threshold

≤0.5 μg./mL.

<0.89 μg./mL.

≤1.28 μg./mL.

PE Present

PE Absent

>0.5 μg./mL.

79

321

≤0.5 μg./mL.

0

26

≥0.89 μg./mL.

79

250

<0.89 μg./mL.

0

97

>1.28 μg./mL.

77

146

≤1.28 μg./mL.

2

201

Sensitivity

Specificity

100%

7.49%

100%

27.95%

97.46%

57.93%

PE = Pulmonary Embolism

against our study data yielded a sensitivity for excluding
PE to be 100% and specificity of 7.49% (Table 2). The authors were able to increase the D-dimer threshold to < 0.89
μg./mL. to maintain a sensitivity of 100% but raise the
specificity to 27.95% (Table 2). Additional analyses of a cutoff value of ≤ 1.28 μg./mL. reduced the sensitivity to 97.47%
but increased the specificity to 57.93% (Table 2). Figure 2
depicts the distribution of D-dimer values between the PE
negative and PE positive sample subgroups.
SECONDARY FINDINGS

Additional data were analyzed to draw further conclusions
and note trends that may clinically assist providers. Regarding demographics, the mean age of the PE positive group
was 61.3 years old (SD 15.6) versus the PE negative group
which was 61.7 years old (SD 16.8). This difference was not
statistically significant (P = 0.86). Furthermore, of the 79
patients with PE, 42 (53.2%) were male while 37 (46.8%)
were female (P = 0.42).
During the peak of COVID-19 at our institution, it became apparent that many of these patients had initial chest
X-rays that demonstrated “multifocal pneumonia” but were
later found to be positive for PE. In this study, those patients who received a chest X-ray (CXR) (N=407), 321
(78.9%) were identified of having infiltrate in X-ray reports.
Those who received pulmonary CT angiography (N=426),
390 (91.6%) were identified to have infiltrate in reports. Although not formally analyzed, these data support the conclusion that infiltrates identified on imaging does not exclude PE in COVID-19 patients.
The authors also compared mortality rates within the analytic sample. Overall, 68 (16.0%) sample patients were deceased at the time of data collection (May-July 2020). The

Figure 1. Age distribution of sample

percentage of patients who died in the “positive for PE”
group (N=12, 15.2%) versus “negative for PE” group (N=56,
16.1%) showed no significant chi square test difference (P =
0.84), although this may have been attributable to the small
sample size.
STUDY LIMITATIONS

Some typical measurement limitations in COVID-19 study
designs include a wide variability in sensitivity of the nasopharyngeal swabs, largely dependent on: a) the types and
quality of specimens obtained,9,10 b) duration of illness at
the time of their testing,11,12 and c) the specific assay that
was used.13,14 This could have led to false negatives which,
in turn, would have resulted in missed data points. During
the study, we did not take into account certain health condi-
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tions (e g., pregnancy, a history of clotting disorder or cancer, ambulatory status, trauma), anticoagulation status, or
other co-morbidities such as end stage renal disease and
other forms of venous thromboembolism or arterial occlusion which may have affected our results.15
Neither did our sample include individuals who underwent alternative diagnostic modalities for venous thromboembolism. As previously mentioned, we also excluded
cases in which CT images were read as “inadequate” due
to motion artifact (i.e., patient movement) and problematic
timing of contrast bolus.

DISCUSSION
COVID-19 has been cited as causing a pro-inflammatory
state which can lead to increased risk for venous thromboembolism.16 Based on these results and those from earlier studies, thrombotic complications such as PE are frequently identified in COVID-19 patients and can lead to
increased morbidity and mortality if not promptly diagnosed.2 The overlap of symptoms has been particularly
challenging in determining whom to perform pulmonary
CT angiography on. In these analyses, utilization of the
D-dimer lab marker may be one tool to assist providers
in determining the need for pulmonary CT angiography in
COVID-19 patients.
As previously mentioned, the utility of D-dimer lab values to rule out PE has apparently only been validated in
non-COVID-19 patients to date.6 The traditional D-dimer
value of ≤ 0.5 μg./mL. serves as an important tool to rule
out PE in patients with a low and intermediate probability
for PE. In our n = 426 sample, we were able to maintain
a sensitivity of 100% to rule out PE observing a D-dimer
threshold of < 0.89 μg./mL while increasing our specificity
to 27.95% from 7.49% when compared to the traditional Ddimer threshold. Despite our increase in specificity, the Ddimer still primarily retains its purpose as a negative predictive tool due to the number of aforementioned comorbid
conditions that can raise D-dimer levels.15
When we observed an increased “< 0.89 ug./mL” D-dimer
threshold, we considerably reduced (i.e., approx.. 97
(22.7%) the number of evidently unnecessary pulmonary CT
angiography scan orders. In comparison, theoretically applying the traditional D-dimer threshold of ≤ 0.5 μg./mL. to
our study only reduced CT scans by 6.1% (i.e., 26 CT scans).
This has significant implications for patient safety, cost utilization, and more appropriate use of hospital resources.
During our study, we found a significant difference in average D-dimer value in the PE positive group compared to
the PE negative group: 9.15 μg./mL. versus 2.95 μg./mL., respectively. Significantly elevated serum thrombogenic proteins such as the D-dimer have also been associated with
increased mortality in COVID-19 patients.17 Although the

Figure 2. Distribution of D-dimer values between
the PE negative and PE positive subgroups.

D-dimer serves primarily as a negative predictive tool,
providers should be vigilant when significantly elevated Ddimer values are obtained in COVID-19 patients. Although
other forms of venous thromboembolism and arterial occlusion were not formally addressed during our study,
providers may consider further development of lower Ddimer thresholds for certain patient subgroups receiving
additional diagnostic studies.15

CONCLUSIONS
Although thrombotic complications such as PE have been
frequently associated with COVID-19, few tools currently
exist to identify patients requiring pulmonary CT angiography. Our study findings indicate an increased D-dimer
threshold can be reasonably used to rule out PE and eliminate unnecessary pulmonary CT angiography scans.
Prompt diagnosis of PE will generally lead to appropriate
therapies and potentially better patient outcomes. Further
studies focusing on alternative diagnostic modalities with
significantly elevated D-dimer cases are certainly necessary
given the associated increased mortality. Further studies
considering how empiric anticoagulation may be warranted
in clinically unstable COVID-19 patients with elevated Ddimer values are needed.
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